ConductScience.org, home

Paper35257531

Medical Management of Patients With Heart Failure and Reduced Ejection Fraction.

Greenberg B. Korean Circ J, 2022. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. Papers, record 35257531. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35257531

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Medical Management of Patients With Heart Failure and Reduced Ejection Fraction.
PubMed
Journal
Korean Circ J
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
1.48
iCite
Revised in PubMed
2022-03-18
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Greenberg BBarryhttps://orcid.org/0000-0002-6605-9385

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References116

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132034017Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study.BMJ Open2020https://conductscience.org/library/papers/32034017PubMed
229526832Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.Circulation2018https://conductscience.org/library/papers/29526832PubMed
321147120Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure.J Mol Cell Cardiol2011https://conductscience.org/library/papers/21147120PubMed
415210610Digitalis therapy for patients in clinical heart failure.Circulation2004https://conductscience.org/library/papers/15210610PubMed
513678870Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.Lancet2003https://conductscience.org/library/papers/13678870PubMed
630075873Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.J Am Coll Cardiol2018https://conductscience.org/library/papers/30075873PubMed
730295807Treatments targeting inotropy.Eur Heart J2019https://conductscience.org/library/papers/30295807PubMed
826022006Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.Eur Heart J2015https://conductscience.org/library/papers/26022006PubMed
924164241Targeting sarcoplasmic reticulum calcium ATPase by gene therapy.Hum Gene Ther2013https://conductscience.org/library/papers/24164241PubMed
1025951506Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.J Clin Pharmacol2015https://conductscience.org/library/papers/25951506PubMed
1131078482Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.JACC Heart Fail2019https://conductscience.org/library/papers/31078482PubMed
1210758966
Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction.
J Am Coll Cardiol2000https://conductscience.org/library/papers/10758966PubMed
138941106Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.Circulation1996https://conductscience.org/library/papers/8941106PubMed
141463530Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.N Engl J Med1992https://conductscience.org/library/papers/1463530PubMed
15411364Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.Am J Cardiol1977https://conductscience.org/library/papers/411364PubMed
163591616Heart rate and cardiovascular mortality: the Framingham Study.Am Heart J1987https://conductscience.org/library/papers/3591616PubMed
1730415602Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med2019https://conductscience.org/library/papers/30415602PubMed
1830415601Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.N Engl J Med2019https://conductscience.org/library/papers/30415601PubMed
1933095032Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.Circulation2021https://conductscience.org/library/papers/33095032PubMed
2024526677Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart.Circ Res2014https://conductscience.org/library/papers/24526677PubMed

See all 116 referencesDownload CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
42793077Nanoparticle-Based Therapies for Myocardial Injury and Heart Failure: A Systematic Review and Translational Appraisal of Preclinical Evidence.Biomolecules2026https://conductscience.org/library/papers/42793077PubMed
42756717Historical Drug Costs Among Elderly Patients Hospitalized with Heart Failure in Canada, 2013-2014 to 2018-2019.CJC Open2026https://conductscience.org/library/papers/42756717PubMed
42486825[Lonicera japonica attenuates oxidative stress and improves post-ischemic heart failure in mice via the STAT3/PGC-1α axis].Nan Fang Yi Ke Da Xue Xue Bao2026https://conductscience.org/library/papers/42486825PubMed
42193343The Influence of Basic Therapy and New Drugs on NO-Dependent Mechanisms of Cardiac Destruction in Chronic Heart Failure.Biomedicines2026https://conductscience.org/library/papers/42193343PubMed
41818254Early administration of renin-angiotensin system inhibitors improves survival and cardiac remodeling in heart failure with preserved ejection fraction.PLoS One2026https://conductscience.org/library/papers/41818254PubMed
40990276
Cardiopulmonary Remodeling In Nondiabetic Patients with Systolic Heart Failure Using Sodium-Glucose Cotransporter 2 Inhibitors: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Curr Cardiol Rev2026https://conductscience.org/library/papers/40990276PubMed
40736158The Biomarker Galaxy: Big Endothelin-1 Joins the Expanding Universe of Heart Failure Prognostication.Korean Circ J2025https://conductscience.org/library/papers/40736158PubMed
39544327Comprehensive Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Reduced Ejection Fraction: A Literature Review.J Clin Med Res2024https://conductscience.org/library/papers/39544327PubMed
39346567Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular and Renal Outcomes in Heart Failure Patients With Type 2 Diabetes: A Literature Review.J Clin Med Res2024https://conductscience.org/library/papers/39346567PubMed
38956938Proteome-wide Characterization and Pathophysiology Correlation in Non-ischemic Cardiomyopathies.Korean Circ J2024https://conductscience.org/library/papers/38956938PubMed
38767446Frailty, Sarcopenia, Cachexia, and Malnutrition in Heart Failure.Korean Circ J2024https://conductscience.org/library/papers/38767446PubMed
38542088Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium.Int J Mol Sci2024https://conductscience.org/library/papers/38542088PubMed
37670168Novel Therapeutic Avenues for Hypertrophic Cardiomyopathy.Am J Cardiovasc Drugs2023https://conductscience.org/library/papers/37670168PubMed
37161744Treatment Strategies of Improving Quality of Care in Patients With Heart Failure.Korean Circ J2023https://conductscience.org/library/papers/37161744PubMed
37161685To Take or Not to Take: The Dilemma With Marginal Donor Heart?Korean Circ J2023https://conductscience.org/library/papers/37161685PubMed
35656934Role of β-Blockers in Chronic Coronary Artery Disease Management in the Percutaneous Coronary Intervention Era: Good Symptom Control or Something More?Korean Circ J2022https://conductscience.org/library/papers/35656934PubMed

Download CSV of cited by

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35257531

GET https://conductscience.org/api/papers/v1/35257531/references?page=2